Tolman MDA Telethon Party

Exciting News

The Food and Drug Administration (FDA) has given the green light to a new gene therapy treatment for Duchenne Muscular Dystrophy (DMD) patients 4-to-5-years-old. The life-extending therapy, ELEVIDYS (delandistrogene moxeparvovec-rokl), was discovered through Muscular Dystrophy Association (MDA) research funded by donors like you.

Thanks to your generous support, the MDA has been able to fund critical research, facilitate innovative clinical trials, and gather the necessary resources to accelerate the development of this revolutionary treatment. Donald Wood, Ph.D., President and CEO of MDA states, “The approval of ELEVIDYS signifies a major leap forward in our collective efforts to combat Duchenne Muscular Dystrophy and provides hope to existing patients and their families.”

47th Annual MDA "Telethon" Save the date: Sunday September 3rd 11 am-4 pm

Thank you for caring!

Telethon Party Schedule